Lucid Diagnostics Inc (LUCD)

Currency in USD
0.3831
-0.0147(-3.70%)
Real-time Data·
LUCD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.37000.4000
52 wk Range
0.30301.6293
Key Statistics
Prev. Close
0.3978
Open
0.4
Day's Range
0.37-0.4
52 wk Range
0.303-1.6293
Volume
1.64M
Average Volume (3m)
5.02M
1-Year Change
-64.2897%
Book Value / Share
0.031
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LUCD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.0000
Upside
+944.11%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Lucid Diagnostics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.0000
(+944.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Needham
Buy3.00+689.68%-MaintainAug 13, 2026
Maxim Group
Buy2.00+426.45%3.00MaintainMay 15, 2026
BTIG
Buy2.50+558.07%-MaintainMar 30, 2026
Needham
Buy3.00+689.68%-MaintainMar 26, 2026
Canaccord
Buy3.00+689.68%-MaintainMar 26, 2026

Lucid Diagnostics Inc SWOT Analysis


Market Disruption
Lucid Diagnostics aims to revolutionize BE-EAC screening with EsoGuard/EsoCheck technology, targeting a $25 billion U.S. market opportunity
Financial Crossroads
Despite 179% YoY revenue growth, LUCD faces challenges with cash burn and revised 2025 revenue projections, reflecting market uncertainties
Reimbursement Hurdles
Progress in clinical validation studies bolsters reimbursement efforts, but pricing pressures could impact future revenue and market adoption
Strategic Outlook
Analysts set price targets between $2.00 and $3.00, as LUCD navigates growth challenges and explores potential market expansion opportunities
Read full SWOT analysis

Lucid Diagnostics Inc Earnings Call Summary for Q3/2026

  • Q3 revenue of $1.2M missed $1.63M forecast; non-GAAP loss of $0.06/share slightly wider than expected $0.0525 amid reimbursement transition.
  • Medicare coverage breakthrough: Novitas paying $1,938.01 per test starting October; record 1,800+ tests performed that month vs 2,871 in entire Q3.
  • Cash position strengthened to $33M pro forma after $15M Series C financing; quarterly burn rate improved to $10.2M, lowest in four quarters.
  • CEO Aklog says Medicare approval transforms commercialization from 'marathon to sprint'; sales force redirected to Medicare population for 90% margin tests.
  • Management expects 'very solid' Q4 with continued Medicare payment growth, though cautioned on holiday seasonality; MolDX pathway for California lab pending.
Last Updated: 11/12/2026, 10:36 PM
Read Full Transcript

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.06 / -0.05
Revenue / Forecast
1.21M / 1.63M
EPS Revisions
Last 90 days

LUCD Income Statement

Compare LUCD to Peers and Sector

Metrics to compare
LUCD
Peers
Sector
Relationship
P/E Ratio
−1.2x0.0x−0.2x
PEG Ratio
−0.020.000.00
Price/Book
12.5x1.5x2.6x
Price / LTM Sales
13.6x2.0x2.7x
Upside (Analyst Target)
-105.4%66.0%
Fair Value Upside
Unlock39.7%10.8%Unlock

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
22.61M11.84%8.99M
Other Institutional Investors
77.75M40.72%30.93M
Public Companies & Retail Investors
90.59M47.44%36.04M
Total
190.95M100.00%75.96M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
PAVmed Inc.20.33%38,816,90315,441
Alyeska Investment Group, L.P.4.64%8,856,8443,523

People Also Watch

0.988
WFF
-7.67%
3.395
GRML
-3.00%
0.0157
SHFS
-31.74%
9.10
AIOK
-3.91%
1.105
QTEX
-3.91%

FAQ

What Is the Lucid Diagnostics (LUCD) Stock Price Today?

The Lucid Diagnostics stock price today is 0.3831 USD.

What Stock Exchange Does Lucid Diagnostics Trade On?

Lucid Diagnostics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lucid Diagnostics?

The stock symbol for Lucid Diagnostics is "LUCD."

What Is the Lucid Diagnostics Market Cap?

As of today, Lucid Diagnostics market cap is 77.4500M USD.

What Is Lucid Diagnostics's Earnings Per Share (TTM)?

The Lucid Diagnostics EPS (TTM) is -0.38.

When Is the Next Lucid Diagnostics Earnings Date?

Lucid Diagnostics will release its next earnings report on Mar 29, 2027.

From a Technical Analysis Perspective, Is LUCD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Lucid Diagnostics Stock Split?

Lucid Diagnostics has split 0 times.

What is the current trading status of Lucid Diagnostics (LUCD)?

As of Nov 17, 2026, Lucid Diagnostics (LUCD) is trading at a price of 0.3831 USD, with a previous close of 0.3978 USD. The stock has fluctuated within a day range of 0.3700 USD to 0.4000 USD, while its 52-week range spans from 0.3030 USD to 1.6293 USD.

What Is Lucid Diagnostics (LUCD) Price Target According to Analysts?

The average 12-month price target for Lucid Diagnostics is 4.0000 USD, with a high estimate of 9.5 USD and a low estimate of 2 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +944.11% Upside potential.

What Is the LUCD Premarket Price?

LUCD's last pre-market stock price is 0.3968 USD. The pre-market share volume is 26,430.0000, and the stock has decreased by -0.0010, or -0.2500%.

What Is the LUCD After Hours Price?

LUCD's last after hours stock price is 0.4190 USD, the stock has decreased by 0.0212, or 5.3300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.